JP6758185B2 - マルチエピトープｔａｒｐペプチドワクチンおよびその使用 - Google Patents

マルチエピトープｔａｒｐペプチドワクチンおよびその使用 Download PDF

Info

Publication number
JP6758185B2
JP6758185B2 JP2016538101A JP2016538101A JP6758185B2 JP 6758185 B2 JP6758185 B2 JP 6758185B2 JP 2016538101 A JP2016538101 A JP 2016538101A JP 2016538101 A JP2016538101 A JP 2016538101A JP 6758185 B2 JP6758185 B2 JP 6758185B2
Authority
JP
Japan
Prior art keywords
tarp
peptide
composition
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016538101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500305A (ja
JP2017500305A5 (enExample
Inventor
ローレン ブイ． ウッド，
ローレン ブイ． ウッド，
ジェイ エー． ベルゾフスキー，
ジェイ エー． ベルゾフスキー，
ブレンダ ディー． ロバーソン，
ブレンダ ディー． ロバーソン，
マサキ アール． テラベ，
マサキ アール． テラベ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2017500305A publication Critical patent/JP2017500305A/ja
Publication of JP2017500305A5 publication Critical patent/JP2017500305A5/ja
Application granted granted Critical
Publication of JP6758185B2 publication Critical patent/JP6758185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016538101A 2013-12-13 2014-12-12 マルチエピトープｔａｒｐペプチドワクチンおよびその使用 Active JP6758185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915948P 2013-12-13 2013-12-13
US61/915,948 2013-12-13
PCT/US2014/070144 WO2015089469A1 (en) 2013-12-13 2014-12-12 Multi-epitope tarp peptide vaccine and uses thereof

Publications (3)

Publication Number Publication Date
JP2017500305A JP2017500305A (ja) 2017-01-05
JP2017500305A5 JP2017500305A5 (enExample) 2018-01-18
JP6758185B2 true JP6758185B2 (ja) 2020-09-23

Family

ID=52432905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538101A Active JP6758185B2 (ja) 2013-12-13 2014-12-12 マルチエピトープｔａｒｐペプチドワクチンおよびその使用

Country Status (7)

Country Link
US (1) US10286050B2 (enExample)
EP (1) EP3079716B1 (enExample)
JP (1) JP6758185B2 (enExample)
AU (1) AU2014361788B2 (enExample)
CA (1) CA2932248C (enExample)
DK (1) DK3079716T3 (enExample)
WO (1) WO2015089469A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368067B1 (en) 2015-10-30 2021-05-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Compositions and methods for the treatment of her2-expressing solid tumors
CN120615012A (zh) * 2022-10-17 2025-09-09 Pds生物科技公司 用于表达TCRγ可变阅读框架蛋白(TARP)的癌症的新型非HLA限制性T细胞疫苗

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
KR100198868B1 (ko) 1991-07-25 1999-06-15 케네쓰 제이. 울코트 세포독성 t 림프구 반응을 유도하는 조성물
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1200585A1 (en) 1999-07-13 2002-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES T-cell receptor gamma alternate reading frame protein, (tarp) and uses thereof
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
AU2003245729A1 (en) * 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7541035B2 (en) 2003-06-05 2009-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
EP2040745B1 (en) 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Also Published As

Publication number Publication date
CA2932248C (en) 2022-08-02
AU2014361788B2 (en) 2019-10-10
WO2015089469A1 (en) 2015-06-18
JP2017500305A (ja) 2017-01-05
EP3079716B1 (en) 2019-05-08
AU2014361788A1 (en) 2016-06-30
CA2932248A1 (en) 2015-06-18
US20160310585A1 (en) 2016-10-27
US10286050B2 (en) 2019-05-14
EP3079716A1 (en) 2016-10-19
DK3079716T3 (da) 2019-08-19

Similar Documents

Publication Publication Date Title
KR102874251B1 (ko) 신생항원 및 이의 용도
JP6444336B2 (ja) ポリペプチド
TWI533882B (zh) 用於治療胃癌和其他癌症的抗腫瘤相關肽及相關抗癌疫苗組合物
US20160022791A1 (en) Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer
CA2522456A1 (en) Nucleotide and cellular vaccine composition
RS53872B1 (sr) Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
AU2018348432B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
JP6032853B2 (ja) 前立腺関連抗原分子由来ｈｌａ結合ペプチドおよびその使用方法
US11712465B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
US20090208518A1 (en) Immunogenic peptides for the treatment of prostate and breast cancer
CA2617009C (en) Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
JP5087925B2 (ja) 新規癌抗原ペプチド及びその用途
US9937250B2 (en) Immunogenic tumor associated stromal cell antigen peptides and methods of their use
JP6758185B2 (ja) マルチエピトープｔａｒｐペプチドワクチンおよびその使用
WO2018032501A1 (zh) 一种新的肿瘤特异性多肽及其应用
RU2832574C2 (ru) Неоантигенные композиции и их использование
US20150202273A1 (en) Prostate-specific tumor antigens and uses thereof
RU2773273C2 (ru) Неоантигены и способы их использования
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS Inventors: Jens Fritsche (Tuebingen, DE) Jens Fritsche (Tuebingen, DE) Toni Weinschenk (Aichwald, DE) Steffen Walter (Reutlingen, DE) Steffen Walter (Reutlingen, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Harpeet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191028

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200901

R150 Certificate of patent or registration of utility model

Ref document number: 6758185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250